NRG Oncology's GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)

被引：4
|
作者：
Zumsteg, Z. [1 ]
Karrison, T. [2 ]
Michaelson, M. D. [3 ]
Tran, P. [4 ]
Kudchadker, R. [5 ]
Feng, F. [6 ]
机构：
[1] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA
[2] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA
[3] Harvard Med Sch, Dept Med Oncol, Massachusetts Gen Hosp, Boston, MA 02115 USA
[4] Johns Hopkins, Dept Radiat Oncol, Baltimore, MD USA
[5] MD Anderson, Dept Radiat Oncol, Houston, TX USA
[6] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
689TiP
引用
收藏
页码：S546 / S546
页数：1
相关论文
共 50 条
  • [41] A RANDOMIZED PHASE II TRIAL OF PROSTATE BOOST IRRADIATION WITH STEREOTACTIC BODY RADIOTHERAPY (SBRT) IN HIGH-RISK PROSTATE CANCER. THE PBS TRIAL
    Douvi, Georgia
    Isfahanian, Naghmeh
    Lukka, Himanshu
    IanDayes
    Quan, Kimmen
    Schnarr, Kara Lynne
    Goldberg, Mira
    Wright, Jim
    Hallock, Abhirami
    Ishkanian, Adrian
    Cuthbert, David
    Swaminath, Anand
    Chow, Tom
    Diamond, Kevin
    Cutz, Jean-Claude
    Kavsak, Peter
    Thabane, Lehana
    Tsakiridis, Theodoros
    RADIOTHERAPY AND ONCOLOGY, 2020, 150 : S87 - S88
  • [42] Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer
    Heymann, Jonas J.
    Benson, Mitchell C.
    O'Toole, Kathleen M.
    Malyszko, Bozena
    Brody, Rachel
    Vecchio, Darleen
    Schiff, Peter B.
    Mansukhani, Mahesh M.
    Ennis, Ronald D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) : 77 - 84
  • [43] Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial
    Phillips, Ryan
    Proudfoot, James A.
    Davicioni, Elai
    Liu, Yang
    Spratt, Daniel Eidelberg
    Feng, Felix Y.
    Simko, Jeff
    Den, Robert Benjamin
    Pollack, Alan
    Rosenthal, Seth A.
    Sartor, A. Oliver
    Sweeney, Christopher
    Attard, Gerhardt
    Patel, Samir
    Straza, Michael Wayne
    Efstathiou, Jason A.
    Shah, Amit
    Rodgers, Joseph P.
    Sandler, Howard M.
    Tran, Phuoc T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Survival analysis of the randomized phase II trial to investigate androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.
    Maluf, Fernando Cotait
    Soares, Andrey
    Bastos, Diogo Assed
    Schutz, Fabio A. B.
    Cronemberger, Eduardo
    Luz, Murilo
    Martins, Suelen P. S.
    Muniz, David Queiroz Borges
    Carcano, Flavio Mavignier
    Smaletz, Oren
    Peixoto, Abio A.
    Gomes, Andrea J.
    Cruz, Felipe Melo
    Franke, Fabio
    Herchenhorn, Daniel
    Gidekel, Rosemarie
    Rebelatto, Taiane Francieli
    Gomes, Rafaela
    Souza, Vinicius Carrera
    Fay, Andre P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP).
    McKenzie, M. R.
    Chi, K. N.
    Neville, A.
    Ellard, S.
    Baerg, B.
    Ruether, D.
    Winquist, E.
    Segal, R.
    Lukka, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 249S - 249S
  • [46] Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial
    Fizazi, Karim
    Faivre, Laura
    Lesaunier, Francois
    Delva, Remy
    Gravis, Gwenaelle
    Rolland, Frederic
    Priou, Frank
    Ferrero, Jean-Marc
    Houede, Nadine
    Mourey, Loic
    Theodore, Cnristine
    Krakowski, Ivan
    Berdah, Jean-Francois
    Baciuchka, Marjorie
    Laguerre, Brigitte
    Flechon, Aude
    Ravaud, Alain
    Cojean-Zelek, Isabelle
    Oudard, Stephane
    Labourey, Jean-Luc
    Chinet-Charrot, Paule
    Legouffe, Eric
    Lagrange, Jean-Leon
    Linassier, Claude
    Deplanque, Gael
    Beuzeboc, Philippe
    Davin, Jean-Louis
    Martin, Anne-Laure
    Habibian, Muriel
    Laplanche, Agnes
    Culine, Stephane
    LANCET ONCOLOGY, 2015, 16 (07): : 787 - 794
  • [47] Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: Pathologic response and PSMA imaging correlates.
    Bastos, Diogo Assed
    Coelho, Rafael
    Cardili, Leonardo
    Galiza, Felipe
    Ilario, Eder Nisi
    Viana, Ublio
    Murta, Claudio Bovolenta
    Guglielmetti, Giuliano
    Cordeiro, Mauricio
    Pontes, Jose, Jr.
    Muniz, David Queiroz Borges
    Silva, Jamile Almeida
    Mota, Jose Mauricio
    De Freitas, Guilherme Fialho
    Leite, Katia Ramos Moreira
    Buchpiguel, Carlos Alberto
    Nahas, William Carlos
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial
    Usmani, Nawaid
    Ghosh, Sunita
    Sanghera, Karan P.
    Ong, Aldrich D.
    Koul, Rashmi
    Dubey, Arbind
    Ahmed, Shahida
    Quon, Harvey
    Yee, Don
    Parliament, Matthew
    Sivananthan, Gokulan
    Hunter, William
    Danielson, Brita
    Rowe, Lindsay
    McDonald, Megan
    Kim, Julian O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 115 (02): : 317 - 326
  • [49] Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial
    Zhuang, Junlong
    Wang, Yuwen
    Zhang, Shun
    Qiu, Xuefeng
    Zhou, Feng
    Fu, Yao
    Wei, Xuedong
    Xu, Linfeng
    Guo, Hongqian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 321 - 321
  • [50] Sexual outcomes in high risk prostate cancer treated with long term androgen deprivation therapy and radiotherapy: results from a phase III trial
    Nabid, Abdenour
    Carrier, Nathalie
    Martin, Andre-Guy
    Bahary, Jean-Paul
    Souhami, Luis
    Duclos, Marie
    Vincent, Francois
    Vass, Sylvie
    Bahoric, Boris
    Archambault, Robert
    Lemaire, Celine
    QUALITY OF LIFE RESEARCH, 2016, 25 : 36 - 36
12345